Efficacy of a Salmonella enterica serovar Abortusovis (S. Abortusovis) inactivated vaccine in experimentally infected gestating ewes. (March 2021)

• Record Type: Journal Article
• Authors: García-Seco, Teresa; Montbrau, Carlos; Fontseca, Mireia; March, Ricard; Sitja, Marta; Domínguez, Lucas; Bezos, Javier
• Is Part Of: Research in veterinary science. Volume 135(2021)
• Page Start: 486
• Page End: 494
• Publication Date: 2021-03
• Subjects: Salmonella Abortusovis -- Experimental infection -- Vaccination -- Sheep -- Abortion; Veterinary medicine -- Periodicals; Veterinary Medicine -- Periodicals; Médecine vétérinaire -- Périodiques; Médecine vétérinaire -- Recherche -- Périodiques; Diergeneeskunde; 636.089
• DOI: 10.1016/j.rvsc.2020.11.017
• Languages: English
• ISSNs: 0034-5288

Abstract

Abstract: Salmonella enterica serovar Abortusovis ( S . Abortusovis) infection is one of the most important causes of infectious late-term abortion as well as birth of weak lambs in sheep in many countries throughout the world. Implementation of protocols based on the application of effective vaccines is one of the most effective approaches for controlling this disease, but variable efficacy has been reported, possibly related to factors associated with the host, the vaccine, the parameters used for determining efficacy and the challenge protocols. In this context, a new commercial inactivated vaccine (INMEVA; Laboratorios Hipra S.A., Spain) was evaluated in 20 control and 17 vaccinated gestating ewes, subcutaneously challenged at 90 days of gestation with 5 × 10 6 colony-forming units (cfu) of a wild strain of S . Abortusovis. Incidence of reproductive failures, bacterial vaginal excretion (by real time PCR), and lamb survival were evaluated as indicators of the vaccine's level of protection. Moreover, humoral response (by ELISA test in serum samples) was studied. Vaccination was showed to be safe under the study conditions. Vaccine efficacy was demonstrated in two different ways: i) it significantly decreased the percentage of abortions [29.4% (5/17) in the vaccinated group compared to the control group (65%; 13/20)] and ii) there was a significant reduction of the overall vaginal excretion in the sampling period (3.05 log cfu/mL ± 0.84 in the vaccinated group vs. 5.68 ± 0.67 in the control group). Given these results, the vaccine evaluated can be considered as an effective alternative for controlling S . Abortusovis infection in ovine flocks. Highlights: Safety & efficacy of a new inactivated vaccine against SAO (INMEVA) were evaluated. Vaccine safety was demonstrated under the study conditions. Vaccine significantly reduced abortions and excretion of SAO in sheep.